MauraLGillisonMD

Oncology • Houston, TX

Professor, Internal Medicine, Ohio State University College of Medicine

Join to view full profile

Dr. Gillison is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gillison's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Fax+1 713-745-7296

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1996 - 1999
Johns Hopkins UniversityInternship, Internal Medicine, 1992 - 1993
Johns Hopkins University School of MedicineClass of 1991

Certifications & Licensure

FL State Medical License 2021 - Present
MD State Medical License 1996 - 2026
TX State Medical License 2016 - 2026
OK State Medical License 2020 - 2021
OH State Medical License 2009 - 2019
IL State Medical License 2016 - 2017

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Elected Member The American Society for Clinical Investigation, 2010

Clinical Trials

Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer Start of enrollment: 2002 Oct 01
Completed
Phase 1
A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC Start of enrollment: 2009 Jul 01
Terminated
Phase 1
Oral HPV Infection in Young Men Start of enrollment: 2007 May 01
Completed
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Start of enrollment: 2010 Mar 31
Active, not recruiting
Phase 3
Everolimus Versus Placebo in Head and Neck Cancer Start of enrollment: 2010 Apr 01
Terminated
Phase 2
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer Start of enrollment: 2011 Jun 01
Active, not recruiting
Phase 3
TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer. Start of enrollment: 2013 Mar 15
Completed
Phase 2
Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2014 Apr 14
Completed
Phase 1
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) Start of enrollment: 2014 May 29
Completed
Phase 3
Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer Start of enrollment: 2014 Jan 01
Completed
Phase 1
Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma Start of enrollment: 2019 Jul 25
Recruiting
Phase 2
Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin Start of enrollment: 2021 Dec 20
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

Phase 1/2 Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas.
Faye M Johnson, Madison P O'Hara, Lacin Yapindi, Peixin Jiang, Hai T Tran
Clinical Cancer Research. 2024-11-26
Elucidating immune-related gene transcriptional programs via factorization of large-scale RNA-profiles.
Shan He, Matthew M Gubin, Hind Rafei, Rafet Basar, Merve Dede
Iscience. 2024-06-21
1 citations
Oncogenic Oral Human Papillomavirus Clearance Patterns over 10 Years.
Gypsyamber D'Souza, Sakshi R Tewari, Tanya Troy, Jennifer Webster-Cyriaque, Dorothy J Wiley
Cancer Epidemiology, Biomarkers & Prevention. 2024-04-03

Lectures

Safety and disease control achieved with the addition of nivolumab (Nivo) to chemoradiotherapy (CRT) for intermediate (IR) and high-risk (HR) local-regionally advanced...
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Funda Meric-Bernstam, M.D., Elected to National Academy of MedicineOctober 21st, 2024
MD Anderson Research Highlights for February 22, 2023February 22nd, 2023
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab plus Atezolizumab in Patients with Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC)January 11th, 2023
Join now to see all

Grant Support

A Therapeutic Vaccine For HPV 16-Positive Head And Neck CancerNational Cancer Institute2007–2008
Oral HPV Infection In Hiv-Infected Men And WomenNational Institute Of Dental &Craniofacial Research2005–2008
Human Oral Papillomavirus Etiology (HOPE) StudyNational Center For Research Resources2007
HOPE Pilot 2National Center For Research Resources2006–2007
Head And Neck Squamous Cell CarcinomaNational Center For Research Resources2006–2007
OSI-774 In Patients With Oral Cavity Or Oropharyngeal CancerNational Center For Research Resources2004–2007
HPV Vaccine Therapy /Correlates In Head/Neck CarcinomaNational Cancer Institute2002